A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS
- PMID: 17854523
- DOI: 10.1016/s1472-6483(10)60339-2
A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS
Abstract
This work evaluated possible advantages of gonadotrophin-releasing hormone (GnRH) antagonist administration as an alternative to coasting in prevention of severe ovarian hyperstimulation syndrome (OHSS) in women undergoing IVF/ intracytoplasmic sperm injection. A prospective randomized study comparing coasting (group A) (n = 96) and GnRH antagonist administration (group B) (n = 94) in patients at risk of OHSS was performed. The primary outcome measure was high quality embryos. The secondary outcome measures were days of intervention, number of oocytes, pregnancy rate, number of cryopreserved embryos and incidence of severe OHSS. There were significantly more high quality embryos (2.87 +/- 1.2 versus 2.21 +/- 1.1; P < 0.0001), and more oocytes (16.5 +/- 7.6 versus 14.06 +/- 5.2; P = 0.02), in group B as compared with group A. There were more days of coasting as compared with days of antagonist administration (2.82 +/- 0.97 versus 1.74 +/- 0.91; P < 0.0001). In conclusion, GnRH antagonist was superior to coasting in producing significantly more high quality embryos and more oocytes as well as reducing the time until HCG administration. There was no significant difference in pregnancy rate between the two groups. No OHSS developed in either group.
Similar articles
-
GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.J Assist Reprod Genet. 2017 Nov;34(11):1537-1545. doi: 10.1007/s10815-017-1010-7. Epub 2017 Aug 3. J Assist Reprod Genet. 2017. PMID: 28776117 Free PMC article. Clinical Trial.
-
The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.Fertil Steril. 2008 Jan;89(1):84-91. doi: 10.1016/j.fertnstert.2007.02.002. Epub 2007 Apr 26. Fertil Steril. 2008. PMID: 17462639 Clinical Trial.
-
Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.Hum Reprod. 2016 Jun;31(6):1253-64. doi: 10.1093/humrep/dew051. Epub 2016 Apr 8. Hum Reprod. 2016. PMID: 27060174 Clinical Trial.
-
The prevention of ovarian hyperstimulation syndrome.J Obstet Gynaecol Can. 2014 Nov;36(11):1024-1033. doi: 10.1016/S1701-2163(15)30417-5. J Obstet Gynaecol Can. 2014. PMID: 25574681 Review. English, French.
-
GnRH-agonist triggering to avoid ovarian hyperstimulation syndrome: a review of the evidence.Curr Drug Targets. 2013 Jul;14(8):843-9. doi: 10.2174/13894501113149990163. Curr Drug Targets. 2013. PMID: 23614678 Review.
Cited by
-
Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.Cochrane Database Syst Rev. 2017 May 23;5(5):CD002811. doi: 10.1002/14651858.CD002811.pub4. Cochrane Database Syst Rev. 2017. PMID: 28535578 Free PMC article.
-
Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis.Cochrane Database Syst Rev. 2025 Jul 1;7(7):CD012586. doi: 10.1002/14651858.CD012586.pub2. Cochrane Database Syst Rev. 2025. PMID: 40590303 Review.
-
GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.J Ovarian Res. 2016 May 17;9(1):29. doi: 10.1186/s13048-016-0237-8. J Ovarian Res. 2016. PMID: 27184139 Free PMC article. Clinical Trial.
-
Does the serum E2 level change following coasting treatment strategy to prevent ovarian hyperstimulation syndrome impact cycle outcomes during controlled ovarian hyperstimulation and in vitro fertilization procedure?Turk J Obstet Gynecol. 2014 Sep;11(3):159-164. doi: 10.4274/tjod.48751. Epub 2014 Sep 15. Turk J Obstet Gynecol. 2014. PMID: 28913010 Free PMC article.
-
GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.J Assist Reprod Genet. 2017 Nov;34(11):1537-1545. doi: 10.1007/s10815-017-1010-7. Epub 2017 Aug 3. J Assist Reprod Genet. 2017. PMID: 28776117 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical